DEFENCE THERAPEUTICS INC
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by Stefan Feulner on October 26th, 2022 | 10:15 CEST
BioNTech, Defence Therapeutics, MorphoSys - The rebound is on the way
The biotech sector is a growth market and, therefore, extremely capital-intensive. Due to the stricter monetary policy of the central banks, investors have given the promising sector the cold shoulder in recent months. Sector indices lost around 30% of their value, while the prices of individual stocks with a full development pipeline halved. The fact that several promising long-term companies are already trading below their cash levels shows that the panic is exaggerated. There are signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Nico Popp on October 17th, 2022 | 12:21 CEST
Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?
After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.
Read
Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST
Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!
Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?
Read
Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST
Evotec, Defence Therapeutics, Formycon - Biotech opportunity!
Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.
Read
Commented by Juliane Zielonka on September 23rd, 2022 | 11:28 CEST
Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health
While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...
Read
Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST
Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?
Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.
Read
Commented by Fabian Lorenz on September 9th, 2022 | 10:53 CEST
300% chance with MorphoSys share? News from BioNTech and Defence Therapeutics
Analysts see a 300% price potential for MorphoSys. However, the latest quarterly figures did not give cause for euphoria. And not all analysts are so positive. On the other hand, BioNTech is currently doing well. The Mainz-based Company has received approval for its Omicron vaccine in the UK. However, the sustainable share price is increasingly determined by the pipeline. There is important news concerning the pipeline at Defence Therapeutics. In preclinical studies for the development of a novel cellular vaccine to fight cancer, the survival rate was 100%. The Canadians' unconventional approach could revolutionize modern medicine. More on the three biotech stocks here.
Read
Commented by Nico Popp on August 29th, 2022 | 12:25 CEST
Biotech stocks - The way it has to go! BioNTech, Defence Therapeutics, Bavarian Nordic
The pharmaceutical and biotech sectors are synonymous with a gold-rush atmosphere. As in the commodities sector, just one discovery can change everything for companies. The best example is BioNTech. Until the pandemic outbreak, the Company was, at best, a household name to biotech nerds. Today, the Palatinate-based company is on top and paying so many taxes that the treasurers of Mainz could pop the corks. We outline three biotech gems and do the future check. We start with BioNTech.
Read